Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Eton Pharmaceuticals, Inc.

NASDAQ: ETON · Life Sciences · 10 alerts · CIK 1710340

Eton Pharmaceuticals, Inc. stories on ALFA USA NewsRead the news →
Share price
$63.88Close, Nov 16
Market cap
$1.84B
Shares outstanding
28.84MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Eton Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:36 PM ET 10-Q
Financial Results ▶ Call

Eton Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $35.2M

Eton Pharmaceuticals reported a significant increase in net revenues to $57.9 million for the third quarter of 2026, driven by strong product sales. The company achieved a net income of $35.2 million for the quarter, aided by a $12.9 million income tax benefit related to the reversal of a deferred tax asset valuation allowance.

Key figure
Net income $35.2M
4:17 PM ET 8-K
Financial Results

Eton Pharmaceuticals Financial Results

Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.

Term
Q3 2026

“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”

Sean Brynjelsen, CEO of Eton Pharmaceuticals

“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”

Sean Brynjelsen, CEO of Eton Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.